Abstract
Knowledge on triptan safety during pregnancy remains limited to their class effect or studies on sumatriptan. Our aim was to evaluate the individual effect of four most frequently used triptans on several pregnancy outcomes. We used the Norwegian prescription database to access information on triptans redeemed by pregnant women living in Norway between 2004 and 2007. This database was linked to the Medical Birth Registry of Norway covering every institutional delivery in Norway and providing information on pregnancy, delivery, maternal and neonatal health. Estimates of associations with pregnancy outcomes were obtained by Generalised Estimation Equations analysis. Of the 181,125 women in our study, 1,465 (0.8 %) redeemed triptans during pregnancy, and 1,095 (0.6 %) redeemed triptans before pregnancy only (disease comparison group). The population comparison group comprised the remaining 178,565 women. Using this group as reference, we found no associations between triptan redemption during pregnancy and congenital malformations. Second trimester redemption was associated with postpartum haemorrhage (adjusted OR 1.57; 95 % CI 1.19–2.07). The disease comparison group had an increased risk of major congenital malformations (adjusted OR 1.48; 95 % CI 1.11–1.97), low birth weight (adjusted OR 1.39; 95 % CI 1.08–1.81), and preterm birth (adjusted OR 1.30; 95 % CI 1.06–1.60). The association of triptans with postpartum hemorrhage could be attributable to decreased platelet agreeability occurring in severe migraine. Likewise, the increased risk of major congenital malformations and other adverse pregnancy outcomes in the disease comparison group might be attributable to migraine severity.
Similar content being viewed by others
References
Ertresvåg J, Zwart J-A, Helde G, Johnsen H-J, Bovim G. Headache and transient focal neurological symptoms during pregnancy, a prospective cohort. Acta Neurol Scand. 2005;111:233–7.
Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003;23(3):197–205.
Melhado E, Maciel JA Jr, Guerreiro CA. Headaches during pregnancy in women with a prior history of menstrual headaches. Arq Neuropsiquiatr. 2005;63(4):934–40. doi:/S0004-282x2005000600006.
Marcus D, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache. 1999;39(9):625–32.
Scharff L, Marcus DA, Turk DC. Headache during pregnancy and in the postpartum: a prospective study. Headache. 1997;37(4):203–10.
Mattsson P, Svardsudd K, Lundberg PO, Westerberg CE. The prevalence of migraine in women aged 40–74 years: a population-based study. Cephalalgia. 2000;20(10):893–9.
Granella F, Sances G, Pucci E, Nappi R, Chiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20(8):701–7.
Maggioni F, Alessi C, Maggino T, Zanchin G. Headache during pregnancy. Cephalalgia. 1997;17(7):765–9.
Facchinetti F, Allais G, Nappi RE, D’Amico R, Marozio L, Bertozzi L, et al. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia. 2009;29(3):286–92. doi:10.1111/j.1468-2982.2008.01704.x.
Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatr Perinat Epidemiol. 2011;25(2):116–23. doi:10.1111/j.1365-3016.2010.01182.x.
Bushnell CD, Jamison M, James AH. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009;338:1–8. doi:10.1136/bmj.b664.
Chen HM, Chen SF, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study. Cephalalgia. 2010;30(4):433–8. doi:10.1111/j.1468-2982.2009.01935.x.
Facchinetti F, Allais G, D’Amico R, Benedetto C, Volpe A. The relationship between headache and preeclampsia: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):143–8. doi:10.1016/j.ejogrb.2004.12.020.
Adeney KL, Williams MA, Miller RS, Frederick IO, Sorensen TK, Luthy DA. Risk of preeclampsia in relation to maternal history of migraine headaches. J Matern Fetal Neonatal Med. 2005;18(3):167–72. doi:10.1080/14767050500260566.
Leveno KJ, Cunningham FG, Alexander JM, Bloom SL, Casey BM, Dashe JS, et al. Williams manual of obstetrics pregnancy complications. 22nd ed. New York: McGraw-Hill; 2007.
Nezvalová-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross sectional analysis of data from a large cohort study. Cephalalgia. 2009;29:1267–76.
Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian mother and child cohort study. Headache. 2010;50:563–75.
Nezvalova-Henriksen K, Spigset O, Nordeng HM. Errata in “Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian mother and child cohort study”. Headache. 2012;52(8):1319–20. doi:10.1111/j.1526-4610.2012.02207.x.
Chu MK, Buse DC, Bigal ME, Serrano D, Lipton RB. Factors associated with triptan use in episodic migraine: results from the American migraine prevalence and prevention study. Headache. 2012;52(2):213–23.
Kαllen B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011;34(8):691–703. doi:10.2165/11590370-000000000-00000.
Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache. 2001;41(4):351–6.
Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache. 2000;40(1):20–4.
GlaxoSmithKline. The Sumatriptan/Naratriptan/Treximet Pregnancy. 2012.
Norwegian Institute of Public Health. The Medical Birth Registry of Norway. Oslo, Norway. http://www.fhi.no/helseregistre/medisinsk-fodselsregister (2013).
Norwegian Institute of Public Health. The Norwegian Prescription Database. Oslo, Norway. http://www.fhi.no/helseregistre/reseptregisteret (2013).
Al-Zirqi I, Stray-Pedersen B, Forsen L, Daltveit AK, Vangen S. Validation study of uterine rupture registration in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand. 2013;. doi:10.1111/aogs.12148.
Vikanes A, Magnus P, Vangen S, Lomsdal S, Grjibovski AM. Hyperemesis gravidarum in the Medical Birth Registry of Norway—a validity study. BMC Pregnancy Childbirth. 2012;12:115. doi:10.1186/1471-2393-12-115.
Engeland A, Bjorge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand. 2009;88(10):1083–9. doi:10.1080/00016340903128454.
Melve KK, Lie RT, Skjaerven R, Van Der Hagen CB, Gradek GA, Jonsrud C, et al. Registration of down syndrome in the Medical Birth Registry of Norway: validity and time trends. Acta Obstet Gynecol Scand. 2008;87(8):824–30. doi:10.1080/00016340802217184.
Baghestan E, Bordahl PE, Rasmussen SA, Sande AK, Lyslo I, Solvang I. A validation of the diagnosis of obstetric sphincter tears in two Norwegian databases, the Medical Birth Registry and the Patient Administration System. Acta Obstet Gynecol Scand. 2007;86(2):205–9. doi:10.1080/00016340601111364.
Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;79(6):435–9.
ATC/DDD Index 2008 [database on the Internet]. Available from: < http://www.whocc.no/atcddd/> (2009). Accessed 3 June 2009.
World Health Organization. International Classification of Diseases. 2013. http://www.who.int/classifications/icd/en/.
Fiore M, Shields KE, Santanello N, Goldberg MR. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia. 2005;25(9):685–8. doi:10.1111/j.1468-2982.2004.00929.x.
Banhidy F, Acs N, Horvath-Puho E, Czeizel AE. Maternal severe migraine and risk of congenital limb deficiencies. Birth Defects Res A. 2006;76(8):592–601. doi:10.1002/bdra.20288.
Williams MA, Peterlin BL, Gelaye B, Enquobahrie DA, Miller RS, Aurora SK. Trimester-specific blood pressure levels and hypertensive disorders among pregnant migraineurs. Headache. 2011;51(10):1468–82. doi:10.1111/j.1526-4610.2011.01961.x.
Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Saf. 2003;26(2):93–107.
Gupta S, Hanff LM, Visser W, Steegers EA, Saxena PR, Vulto AG, et al. Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy. J Hypertens. 2006;24(7):1345–53. doi:10.1097/01.hjh.0000234115.40648.88.
Blair EM, Nelson KB. Migraine and preterm birth. J perinatol. 2011;31(6):434–9. doi:10.1038/jp.2010.148.
Marozio L, Facchinetti F, Allais G, Nappi RE, Enrietti M, Neri I, et al. Headache and adverse pregnancy outcomes: a prospective study. Eur J Obstet Gynecol Reprod Biol. 2012;161(2):140–3. doi:10.1016/j.ejogrb.2011.12.030.
Cripe SM, Sanchez S, Lam N, Sanchez E, Ojeda N, Tacuri S, et al. Depressive symptoms and migraine comorbidity among pregnant Peruvian women. J Affect Disord. 2010;122(1–2):149–53. doi:10.1016/j.jad.2009.07.014.
Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol. 2008;64(1):1–8. doi:10.1007/s00228-007-0391-4.
Melve K, Lie R, Skjærven R, Van Der Hagen C, Gradek G, Jonsrud C, et al. Registration of down syndrome in the Medical Birth Registry of Norway: validity and time trends. Acta Obstet Gynecol Scand. 2008;87:824–30.
Kubon C, Sivertsen A, Vindenes HA, Abyholm F, Wilcox A, Lie RT. Completeness of registration of oral clefts in a medical birth registry: a population-based study. Acta Obstet Gynecol Scand. 2007;86(12):1453–7. doi:10.1080/08037050701645090.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Nezvalová-Henriksen, K., Spigset, O. & Nordeng, H. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 28, 759–769 (2013). https://doi.org/10.1007/s10654-013-9831-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-013-9831-x